Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Advisory committee to evaluate FDA's orlistat review

This article was originally published in The Tan Sheet

Executive Summary

The Pediatric Advisory Committee's March 22 meeting 1agenda includes a "brief follow-up" on FDA's August 2009 "early communication" letter concerning orlistat, the active ingredient in the OTC weight-loss drug alli (60 mg) and Rx Xenical (120 mg). FDA received 32 reports of serious liver injury in patients taking orlistat between 1999, when it first approved Xenical, and 2008; FDA approved alli in 2007 (2"The Tan Sheet" Aug. 31, 2009). The meeting in Bethesda, Md., will include safety reviews on oral and topical drugs for children. FDA will accept written submissions for the meeting through March 8. Oral presentations from the public are scheduled for 1 p.m. to 2 p.m. Requests to make presentations are due by Feb. 28
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS103809

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel